J&J Q3 Report Sinks Shares 6%, Drags Pharma Sector

Johnson & Johnson's quarterly report revealed weak growth in its Medical Devices division, causing its stock to fall nearly 6% on Wall Street and dragging down other pharmaceutical companies. The report signals potential sector-wide headwinds for medical device growth, though the impact is company-specific and not indicative of broader market direction.